<SEC-DOCUMENT>0001628280-23-015693.txt : 20230504
<SEC-HEADER>0001628280-23-015693.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504160159
ACCESSION NUMBER:		0001628280-23-015693
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		23888486

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20230504.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:64723073-7203-40ac-923e-438e9529dddb,g:3aa454d5-a94c-421a-a8fe-0f014353d992,d:f38a364b082f4a81acb53cb1ce2ef79d--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20230504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF80L2ZyYWc6YzAxN2I0Y2UxMDNiNGQ2MWI3NzAxNDdkNmJkYmMxZDgvdGFibGU6M2QxNzNlYmMzMzllNDZhZjk1MjhiOGNkZDIwMmYxY2QvdGFibGVyYW5nZTozZDE3M2ViYzMzOWU0NmFmOTUyOGI4Y2RkMjAyZjFjZF8yLTEtMS0xLTQ2NzA3_18126930-6576-40a0-8be0-78dae3c41e2c">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF80L2ZyYWc6YzAxN2I0Y2UxMDNiNGQ2MWI3NzAxNDdkNmJkYmMxZDgvdGFibGU6M2QxNzNlYmMzMzllNDZhZjk1MjhiOGNkZDIwMmYxY2QvdGFibGVyYW5nZTozZDE3M2ViYzMzOWU0NmFmOTUyOGI4Y2RkMjAyZjFjZF8zLTEtMS0xLTQ2NzA3_23cd8931-d901-4dcf-b219-d02314a92fb9">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20230504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if38a364b082f4a81acb53cb1ce2ef79d_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc0_a84de3a5-9a7f-4bbd-8633-3ed1ac072061">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yMjg_cb0fec38-0b5e-448a-a20d-75bbb3215162">May 4, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20230504_g1.jpg" alt="crdflogo.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc4_291f44eb-7da4-476a-b00f-8c314446ec51">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6ZjcxMTA0M2FkMGI4NDZkY2E4ZGY2MzJkOTNiODM3YjIvdGFibGVyYW5nZTpmNzExMDQzYWQwYjg0NmRjYThkZjYzMmQ5M2I4MzdiMl8wLTAtMS0xLTQ2NzA3_770894ca-06ac-457e-8025-e8b626851c85">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6ZjcxMTA0M2FkMGI4NDZkY2E4ZGY2MzJkOTNiODM3YjIvdGFibGVyYW5nZTpmNzExMDQzYWQwYjg0NmRjYThkZjYzMmQ5M2I4MzdiMl8wLTEtMS0xLTQ2NzA3_de0be299-e073-4594-9221-e49a594d4a5a">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6ZjcxMTA0M2FkMGI4NDZkY2E4ZGY2MzJkOTNiODM3YjIvdGFibGVyYW5nZTpmNzExMDQzYWQwYjg0NmRjYThkZjYzMmQ5M2I4MzdiMl8wLTItMS0xLTQ2NzA3_54c8f023-38c0-4c28-a782-b121a05e825e">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc2_6b546bb8-2414-4338-92b4-5c3e9c6cfc38">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc1_65a0cc29-2d94-4a1c-94f7-a0990f7045d2">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgx_b1faa40c-65f2-44d8-983f-f83de3aaaf03">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgy_cb5d677f-7366-49b4-9c93-8b14a2a27dc7">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc3_c3fa3177-ef3c-4641-b38a-7215305e5b55">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc5_687716f3-73b6-45d3-a5f7-e24afc1ab13d">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6OGVjZmFmYjZhNzRjNDVlZGFiMGUwM2E1M2MwNzExNzMvdGFibGVyYW5nZTo4ZWNmYWZiNmE3NGM0NWVkYWIwZTAzYTUzYzA3MTE3M18xLTAtMS0xLTQ2NzA3_4e555e21-3782-4725-800b-dc5fe6b7daea">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6OGVjZmFmYjZhNzRjNDVlZGFiMGUwM2E1M2MwNzExNzMvdGFibGVyYW5nZTo4ZWNmYWZiNmE3NGM0NWVkYWIwZTAzYTUzYzA3MTE3M18xLTItMS0xLTQ2NzA3_64b72a38-ab5b-4358-a23c-ba910696efa0">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzcw_654788ac-845d-4583-9367-aa4f8ee8ba2a">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgw_10d9f622-0be2-40dd-9607-e221e8d3e707">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzcx_d6ed8b08-13be-472b-b049-182aca22ac87">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzcy_b6caf60f-0184-4e06-95d4-01b91ace242d">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgz_a216ef5a-29ab-4ff1-acac-7b79ab5a7268">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Results of Operations and Financial Conditions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2023.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf033123-q12023pr.htm">Press Release of Cardiff Oncology, Inc. dated May 4, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> May 4, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>crdf033123-q12023pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic98aff8ecc2f44cc9ea77968aee9785d_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:270px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS&#47;NRAS-mutated Metastatic Colorectal Cancer (mCRC)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Introduced full membership of Scientific Advisory Board (SAB)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Cash, cash equivalents, and short-term investments of approximately&#160;$97 million&#160;as of&#160;March 31, 2023, projected runway into 2025</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SAN DIEGO,&#160;May 4, 2023&#160;-&#160;Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-quarter ended&#160;March 31, 2023, and provided a business update.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We are delighted to have dosed the first patient in our Phase 2 ONSEMBLE trial. This randomized trial will evaluate the efficacy of onvansertib combined with standard of care in patients with KRAS&#47;NRAS-mutated mCRC, who historically have limited treatment options,&#8221; said&#160;Mark Erlander, PhD, Chief Executive Officer of Cardiff Oncology. &#8220;In addition, we are excited to have appointed Fairooz Kabbinavar, MD, FACP, as our new Chief Medical Officer, who brings deep expertise in the treatment of patients with CRC as well as expertise in using bevacizumab in the clinical setting. We believe Dr. Kabbinavar adds significant value to our clinical development program for onvansertib. We also formally introduced the full membership of our Scientific Advisory Board, a group of highly esteemed oncology experts who are providing a diverse range of insights that strengthen our clinical programs.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upcoming potential milestones</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.5pt">Metastatic pancreatic ductal adenocarcinoma (mPDAC) data readout from Phase 2 trial expected in mid-2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.5pt">Small cell lung cancer (SCLC) data readout from investigator-initiated (with UPMC) Phase 2 trial expected in mid-2023</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.5pt">Triple negative breast cancer (TNBC) data readout from investigator-initiated (with Dana-Farber Cancer Institute) Phase&#160;1b&#47;2 trial expected in the fourth-quarter of 2023 or first-quarter of 2024</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.5pt">mCRC randomized data readout from Phase 2 ONSEMBLE trial expected in the second-half of 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company Highlights for the quarter ended March 31, 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Announced the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dr. Kabbinavar oversees the clinical development program for the Company's investigational drug onvansertib and reports directly to Chief Executive Officer,&#160;Mark Erlander, PhD.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Formally introduced the full membership of its Scientific Advisory Board (SAB). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The SAB is comprised of a distinguished group of academic and industry experts who bring depth and breadth of knowledge in oncology drug development, clinical trial design, translational science and clinical research. In most cases, these individuals have been advising the Company for several years and will now collectively serve a critical role as we advance the clinical development of </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">onvansertib. The Company anticipates that over time the membership of the SAB may expand to add additional expertise in new indications or stages of clinical development.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:13.8pt">Announced First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer.</font><font style="color:#ed7d31;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Phase 2 ONSEMBLE trial includes patients with mCRC who have a documented KRAS or NRAS mutation and have previously received one prior chemotherapy regimen with or without bevacizumab in the first line metastatic setting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patients are being randomized to onvansertib plus FOLFIRI&#47;bevacizumab versus FOLFIRI&#47;bevacizumab (standard of care).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">First-Quarter 2023 Financial Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Liquidity, cash burn, and cash runway</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As of&#160;March 31, 2023, Cardiff Oncology had approximately&#160;$97.0 million&#160;in cash, cash equivalents, and short-term investments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Net cash used in operating activities for the first quarter of 2023 was approximately&#160;$8.7 million, a decrease of approximately&#160;$1.5 million&#160;from&#160;$10.2 million&#160;for the same period in 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Operating results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total operating expenses were approximately&#160;$12.1 million&#160;for the three months ended March 31 2023, an increase of&#160;$1.0 million&#160;from&#160;$11.1 million&#160;for the same period in 2022. The increase in operating expenses was primarily due to higher costs associated with clinical programs and outside service costs related to the development of the company&#8217;s lead drug candidate, salaries and staff costs primarily due to increased headcount.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Cardiff Oncology, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS&#47;NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended&#160;December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Cardiff Oncology Contact&#58;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">James Levine&#160;<br>Chief Financial Officer&#160;<br>858-952-7670&#160;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">jlevine&#64;cardiffoncology.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Investor Contact&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;<br>Kiki Patel, PharmD &#160;<br>Gilmartin Group&#160;&#160;<br>332-895-3225<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">Kiki&#64;gilmartinir.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Media Contact&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;<br>Richa Kumari&#160;<br>Taft Communications&#160;&#160;<br>551 344-5592&#8239;&#160;&#160;<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%;text-decoration:underline">richa&#64;taftcommunications.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;</font></div><div style="margin-bottom:15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">SOURCE Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic98aff8ecc2f44cc9ea77968aee9785d_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands, except for per share amounts)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:68.714%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,208&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,135&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,148&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,052)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,074)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,223)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,993)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,229)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,999)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,231&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="ic98aff8ecc2f44cc9ea77968aee9785d_7"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Balance Sheets</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,951&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,109&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,753&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,284&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,549&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,148&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,046&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,848&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,503&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,549&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,191&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ic98aff8ecc2f44cc9ea77968aee9785d_10"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Cash Flows</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,223)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,993)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(924)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,659)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,249)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases, maturities and sales of short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,529&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,329&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,358&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,330)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,109&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,017&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,052&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crdf-20230504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:64723073-7203-40ac-923e-438e9529dddb,g:3aa454d5-a94c-421a-a8fe-0f014353d992-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20230504" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20230504">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20230504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>crdf-20230504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:64723073-7203-40ac-923e-438e9529dddb,g:3aa454d5-a94c-421a-a8fe-0f014353d992-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_3401f199-2ce7-474d-bb27-2db0e46a424f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2cee4652-1938-4f6a-869b-10a226c3ba32_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_77e8fd89-e902-4a79-aac5-a643ea5d9ba3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f4b1e687-4032-4c0e-b43c-12fd908aa863_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_43d3f7da-4bd6-4f21-88e1-a0e124d8308a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b2f5b35e-8ff6-4ad5-b9f0-5c876642ca20_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_74d5071f-9b8e-4b31-b54d-67c233bef8db_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c99c355e-b117-4e0b-b28b-b1c05fb26b6d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_46723e11-b485-48e2-8d18-105f26086954_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_821fe607-e57d-4e24-b1e0-1d87040db682_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7f0d4aa6-0553-41e0-b4a1-9c51fc307c67_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6ea99521-2e10-49db-a9e7-2e9403f8aa81_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_851610fc-f8b6-410e-9738-5fb6ae1dd20f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_89ffe32c-785d-4e0b-a0eb-dc48fa1547f7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ad22b8cf-2e78-45aa-9fa6-8adfc135b867_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_acd92e76-79e7-411e-a77c-4f6c26532faf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7ce49f39-9f88-453e-9b22-cb8c2888a004_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6b1cfb56-dfce-4840-8575-2b7c42985cd4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5f72ae9a-5215-4906-8229-04eafbf7540e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_66a07864-881b-486d-82a4-c6342de5b3a4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ba2f053f-b2ce-4c85-a3c1-75f57209e310_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>crdf-20230504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:64723073-7203-40ac-923e-438e9529dddb,g:3aa454d5-a94c-421a-a8fe-0f014353d992-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20230504.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1ae15d62-503c-4a62-83ff-9ebb9f63677f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_DocumentType_1ae15d62-503c-4a62-83ff-9ebb9f63677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ff8b5a40-54b3-4d63-a146-3ff548ec6633" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_DocumentPeriodEndDate_ff8b5a40-54b3-4d63-a146-3ff548ec6633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_72b63591-6147-4ea8-8c93-a5c858aa49c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityRegistrantName_72b63591-6147-4ea8-8c93-a5c858aa49c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_098cd7e0-0a17-4ec9-b905-f9b14daa912a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityFileNumber_098cd7e0-0a17-4ec9-b905-f9b14daa912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_57e6afd3-9ebc-404d-86e1-17e160fc14ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityTaxIdentificationNumber_57e6afd3-9ebc-404d-86e1-17e160fc14ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b02a0b6f-7047-45be-a2ae-e337e5f5f98c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityAddressAddressLine1_b02a0b6f-7047-45be-a2ae-e337e5f5f98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_545dc7ca-3cb5-41de-8e7c-f746b8cbf20c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityAddressStateOrProvince_545dc7ca-3cb5-41de-8e7c-f746b8cbf20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4488aeb3-5d1c-4eb8-9d74-cf5cad6c221b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityAddressPostalZipCode_4488aeb3-5d1c-4eb8-9d74-cf5cad6c221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1f0e0c00-52cd-4bc2-91f7-5df4270d29d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityAddressCityOrTown_1f0e0c00-52cd-4bc2-91f7-5df4270d29d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_411fa9f4-00e0-43e2-b315-bd34148364ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_CityAreaCode_411fa9f4-00e0-43e2-b315-bd34148364ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_abf6aee2-5afa-4d07-a387-34d056956db0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_LocalPhoneNumber_abf6aee2-5afa-4d07-a387-34d056956db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_27d60bbe-f4c2-445a-b143-1accfe45bf16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_Security12bTitle_27d60bbe-f4c2-445a-b143-1accfe45bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7240a667-7b27-40b3-a300-8f381816814d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_TradingSymbol_7240a667-7b27-40b3-a300-8f381816814d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_43bcc871-14f8-49bf-9786-54bd98147da8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_WrittenCommunications_43bcc871-14f8-49bf-9786-54bd98147da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_498ec945-f641-4949-b7a0-0169a596cdd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_SolicitingMaterial_498ec945-f641-4949-b7a0-0169a596cdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_5449c1ff-c26a-4afd-b368-5df8999ac332" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_PreCommencementTenderOffer_5449c1ff-c26a-4afd-b368-5df8999ac332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4738545d-5f9c-4115-a758-df638748a39b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4738545d-5f9c-4115-a758-df638748a39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_49943cc3-a95e-42a1-9f64-a917386821f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityEmergingGrowthCompany_49943cc3-a95e-42a1-9f64-a917386821f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_660fd8a9-db5d-4d57-9200-0506c4f5774e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_660fd8a9-db5d-4d57-9200-0506c4f5774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4d132f9c-c147-46ef-9425-f1a0a15dc3d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_EntityCentralIndexKey_4d132f9c-c147-46ef-9425-f1a0a15dc3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2a23a051-0c65-49e0-8e03-df89974fc112" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd5f304-b6b8-4e3c-af7d-65ff950700eb" xlink:to="loc_dei_AmendmentFlag_2a23a051-0c65-49e0-8e03-df89974fc112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crdf-20230504_g1.jpg
<TEXT>
begin 644 crdf-20230504_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
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M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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5 7)+M=N/[L%'     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139682970982672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>crdf-20230504_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20230504.xsd" xlink:type="simple"/>
    <context id="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF80L2ZyYWc6YzAxN2I0Y2UxMDNiNGQ2MWI3NzAxNDdkNmJkYmMxZDgvdGFibGU6M2QxNzNlYmMzMzllNDZhZjk1MjhiOGNkZDIwMmYxY2QvdGFibGVyYW5nZTozZDE3M2ViYzMzOWU0NmFmOTUyOGI4Y2RkMjAyZjFjZF8yLTEtMS0xLTQ2NzA3_18126930-6576-40a0-8be0-78dae3c41e2c">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF80L2ZyYWc6YzAxN2I0Y2UxMDNiNGQ2MWI3NzAxNDdkNmJkYmMxZDgvdGFibGU6M2QxNzNlYmMzMzllNDZhZjk1MjhiOGNkZDIwMmYxY2QvdGFibGVyYW5nZTozZDE3M2ViYzMzOWU0NmFmOTUyOGI4Y2RkMjAyZjFjZF8zLTEtMS0xLTQ2NzA3_23cd8931-d901-4dcf-b219-d02314a92fb9">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc0_a84de3a5-9a7f-4bbd-8633-3ed1ac072061">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yMjg_cb0fec38-0b5e-448a-a20d-75bbb3215162">2023-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc4_291f44eb-7da4-476a-b00f-8c314446ec51">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6ZjcxMTA0M2FkMGI4NDZkY2E4ZGY2MzJkOTNiODM3YjIvdGFibGVyYW5nZTpmNzExMDQzYWQwYjg0NmRjYThkZjYzMmQ5M2I4MzdiMl8wLTAtMS0xLTQ2NzA3_770894ca-06ac-457e-8025-e8b626851c85">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6ZjcxMTA0M2FkMGI4NDZkY2E4ZGY2MzJkOTNiODM3YjIvdGFibGVyYW5nZTpmNzExMDQzYWQwYjg0NmRjYThkZjYzMmQ5M2I4MzdiMl8wLTEtMS0xLTQ2NzA3_de0be299-e073-4594-9221-e49a594d4a5a">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6ZjcxMTA0M2FkMGI4NDZkY2E4ZGY2MzJkOTNiODM3YjIvdGFibGVyYW5nZTpmNzExMDQzYWQwYjg0NmRjYThkZjYzMmQ5M2I4MzdiMl8wLTItMS0xLTQ2NzA3_54c8f023-38c0-4c28-a782-b121a05e825e">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc2_6b546bb8-2414-4338-92b4-5c3e9c6cfc38">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc1_65a0cc29-2d94-4a1c-94f7-a0990f7045d2">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgx_b1faa40c-65f2-44d8-983f-f83de3aaaf03">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgy_cb5d677f-7366-49b4-9c93-8b14a2a27dc7">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc3_c3fa3177-ef3c-4641-b38a-7215305e5b55">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzc5_687716f3-73b6-45d3-a5f7-e24afc1ab13d">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6OGVjZmFmYjZhNzRjNDVlZGFiMGUwM2E1M2MwNzExNzMvdGFibGVyYW5nZTo4ZWNmYWZiNmE3NGM0NWVkYWIwZTAzYTUzYzA3MTE3M18xLTAtMS0xLTQ2NzA3_4e555e21-3782-4725-800b-dc5fe6b7daea">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGFibGU6OGVjZmFmYjZhNzRjNDVlZGFiMGUwM2E1M2MwNzExNzMvdGFibGVyYW5nZTo4ZWNmYWZiNmE3NGM0NWVkYWIwZTAzYTUzYzA3MTE3M18xLTItMS0xLTQ2NzA3_64b72a38-ab5b-4358-a23c-ba910696efa0">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzcw_654788ac-845d-4583-9367-aa4f8ee8ba2a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgw_10d9f622-0be2-40dd-9607-e221e8d3e707">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzcx_d6ed8b08-13be-472b-b049-182aca22ac87">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzcy_b6caf60f-0184-4e06-95d4-01b91ace242d">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5d1de43e458b4927af8acab56c583b20_D20230504-20230504"
      id="id3VybDovL2RvY3MudjEvZG9jOmYzOGEzNjRiMDgyZjRhODFhY2I1M2NiMWNlMmVmNzlkL3NlYzpmMzhhMzY0YjA4MmY0YTgxYWNiNTNjYjFjZTJlZjc5ZF8xL2ZyYWc6YzMxN2FkYWE4YjA5NDYyNGE3ZDc5ZGE1Zjc4MmZiMDgvdGV4dHJlZ2lvbjpjMzE3YWRhYThiMDk0NjI0YTdkNzlkYTVmNzgyZmIwOF8yNzgz_a216ef5a-29ab-4ff1-acac-7b79ab5a7268">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #R I%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  \@*16#J+BDN\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.FW9#E&7"]-.("$Q"<0M2KPMHFFBQ*C=VY.6K1."!^ 8^\_G
MSY);'83V$9^C#QC)8KH;7=<GH<.&G8B" $CZA$ZE,B?ZW#SXZ!3E9SQ"4/I#
M'1%JSM?@D)11I& "%F$A,MD:+71$13Y>\$8O^/ 9NQEF-&"'#GM*4)45,#E-
M#.>Q:^$&F&"$T:7O IJ%.%?_Q,X=8)?DF.R2&H:A')HYEW>HX.WI\65>M[!]
M(M5KS+^2%70.N&'7R:_-PW:_8[+F=5/P5<'O]S47O!*K]?OD^L/O)NR\L0?[
MCXVO@K*%7W<AOP!02P,$%     @ /("D5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&P#W4P7;J'W'G0;KP_SD7U!+ P04    "  \@*16GZ ;\+$"  #B#   #0
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M?P%02P$"% ,4    "  \@*16!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #R I%8.HN*2[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( #R I%:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ /("D5@E6-TP:!   V \  !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( #R I%:?H!OPL0(  .(,   -              "  5X,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ /("D5I>*NQS     $P(   L
M ( !.@\  %]R96QS+RYR96QS4$L! A0#%     @ /("D5JK$(A8S 0  (@(
M  \              ( !(Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M #R I%8D'INBK0   /@!   :              "  8,1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #R I%9ED'F2&0$  ,\#   3
M              "  6@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  +(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20230504.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="crdf-20230504.htm">crdf-20230504.htm</File>
    <File>crdf-20230504.xsd</File>
    <File>crdf-20230504_lab.xml</File>
    <File>crdf-20230504_pre.xml</File>
    <File>crdf033123-q12023pr.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20230504_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20230504.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 21
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "crdf-20230504.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20230504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20230504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20230504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 22,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 21,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20230504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230504.htm",
      "contextRef": "i5d1de43e458b4927af8acab56c583b20_D20230504-20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardiffoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20230504.htm",
      "contextRef": "i5d1de43e458b4927af8acab56c583b20_D20230504-20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-015693-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015693-xbrl.zip
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M\M@;0!3!0'.R?A]4G2-5W=R@[D#AOJP@Y=B=6@QG7)7J-(T_":,8_35,[CU
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MSWU)G9[VQ,L+(0M=OS:XT+#^+NG]!Z%MIBI=5F$?;^=,%E.M8ZW;4 >@)"
MJX@"$B4,^) B%/& T0#9";IEII$*6Z/UZG"])5Y;@;<1W%7HST#;,(*W9\Q!
M^ ?8Z!$ VBP/' @..+@;$ [=X!H8W@FA%\EB]4M7%]*?QK$D2I $R 0B@&F<
M $JY?A*-<"!I*!(=%>R"0L,L(PT(*X@OUQ>> >M]RJ1M0&@BMFLPZ$G7,('
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M1<[*'OV0[)&.QX[A8*S=D5B;P[";G\2YOCI]L7XE7?XWWM,7_P=02P,$%
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M=R\+ACN?8=8QI!3\V;TJWTRNSZS%B37T([>A^'E(1>U?5_X7G'F7,6:YM(*
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MC&S1&U^A#[*'_D[L,8;9*3GDO&Y:6_Y57)W4/BR%R#(;L%"6GN($&) ?X[4
M%Z6S7CG&Z+B]\K>Q![DC^T[<L3FK4_+&"1Z^31?U3;6DD03B"&ZCF/,@<L?
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M".X<UD9&!A#,4C X.^)'B@FJC-&XC>;2B^##3#+YON-X8B?AC]/*U>FJ3KT
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MJQGCR4BA^!X6N">[_K$#T(H !I#]+N->"-#U>5?\IU3\:] ]8#IPYJ^8(6)
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MS4A(HZD0-9R!5H%OB8F:E!#[@F!I@(>C4 ?"[P)H_NQLXQGJ8LR"F=-P?PQ
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M*H\Q??%I(!N>U[+>02>-@P5?2L'Y#ELZZ^;5P!T?*O*1>W1DZVU/B!7GT:>
M!#-'B>2'A7QXY<-"0(442T:-;'Q:2+U8:RV__>R#+:K%>K/UK&%7WZM5=@-L
M:SV MG<R1"K."!@?C\'6/%XA:PAX<O#R)B<F/">27CSUUX^E3[6>MDG/"&AV
MMS1UW8AI)T!F=XOA* CPQ&A.E%]W>^&=)K=V-L9;6%]\QK79)=;!7\2W2#YP
M#T^P>U'9(J_(O/*<[)I5LI^9YTI0&BMGLD0S6=VJ5/?(9&]A&<1M3P5A 9R[
M/I-T@'M_D3)>*]V;OC[VIFVU:IMF<_-5!J]%G:;5*B=W?]E,N&.GCD-'Z;(
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MPG^]L.]]^']02P$"% ,4    "  \@*16U8[Z$^D3  !VE@  $0
M    @ $     8W)D9BTR,#(S,#4P-"YH=&U02P$"% ,4    "  \@*16V7U?
M[FT"  "#!P  $0              @ $8%   8W)D9BTR,#(S,#4P-"YX<V10
M2P$"% ,4    "  \@*16I]:K[P,*  "L"@  %               @ &T%@
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4!08     !@ & (L!  !N3@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
